American Century Companies Inc. Has $236,000 Stake in Personalis, Inc. $PSNL

American Century Companies Inc. grew its position in Personalis, Inc. (NASDAQ:PSNL) by 33.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,377 shares of the company’s stock after buying an additional 17,056 shares during the quarter. American Century Companies Inc. owned 0.08% of Personalis worth $236,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in PSNL. Aberdeen Group plc boosted its stake in shares of Personalis by 472.3% in the 1st quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock valued at $5,984,000 after purchasing an additional 1,406,895 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in Personalis by 120.8% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 55,583 shares of the company’s stock valued at $195,000 after purchasing an additional 30,415 shares during the last quarter. Howland Capital Management LLC lifted its holdings in shares of Personalis by 7.7% in the 1st quarter. Howland Capital Management LLC now owns 282,808 shares of the company’s stock worth $993,000 after acquiring an additional 20,200 shares during the last quarter. XTX Topco Ltd increased its stake in shares of Personalis by 147.0% in the first quarter. XTX Topco Ltd now owns 82,666 shares of the company’s stock worth $290,000 after buying an additional 49,197 shares during the period. Finally, ARK Investment Management LLC lifted its position in shares of Personalis by 6.1% in the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company’s stock worth $25,231,000 after purchasing an additional 412,762 shares during the period. 61.91% of the stock is owned by institutional investors.

Personalis Price Performance

Shares of PSNL stock opened at $5.24 on Friday. The firm has a market capitalization of $464.68 million, a PE ratio of -4.09 and a beta of 1.76. Personalis, Inc. has a 1-year low of $2.83 and a 1-year high of $7.79. The business’s fifty day moving average price is $5.65 and its 200 day moving average price is $4.83.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on PSNL shares. HC Wainwright cut their price objective on shares of Personalis from $9.00 to $8.50 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Guggenheim initiated coverage on Personalis in a research report on Thursday, May 15th. They set a “buy” rating and a $6.00 target price for the company. BTIG Research set a $6.00 target price on Personalis in a research note on Wednesday, August 6th. Finally, Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $7.42.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.